HCPCS code J0587 – RimabotulinumtoxinB (Myobloc) injection

Key takeaways

HCPCS code J0587 covers rimabotulinumtoxinB (Myobloc) and is billed per 100 units, so a 2,500-unit dose is reported as 25 units.

Myobloc’s FDA-approved indications are cervical dystonia and chronic sialorrhea in adults, and off-label claims carry a higher denial risk.

Medicare Part B pays J0587 at ASP plus 6% in the office setting, and CMS updates the rate every quarter.

J0587 covers the drug only, so the injection is billed separately, typically with CPT 64616 for cervical dystonia.

Pabau, the practice management platform we build, keeps the dose, injection sites and claim details in one patient record.

HCPCS Code J0587: Definition and official descriptor

HCPCS Code J0587 is the CMS code for “injection, rimabotulinumtoxinB, 100 units.“

It sits in the J-series of HCPCS Level II codes, which covers drugs administered other than by mouth. The code identifies Myobloc, the only commercially available rimabotulinumtoxinB product in the US. Medicare Part B and most commercial health plans use it for reimbursement.

The key number in that descriptor is 100. Each billing unit of J0587 represents 100 units of drug, so a patient receiving 2,500 units of Myobloc is billed 25 units of J0587. This trips up billers who also handle onabotulinumtoxinA (Botox, J0585), where one billing unit equals one drug unit.

Drug overview: RimabotulinumtoxinB (Myobloc)

RimabotulinumtoxinB is a botulinum toxin type B preparation. It differs from the type A products (onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA) in both mechanism and clinical profile. Type B toxin acts strongly on autonomic cholinergic nerves, which explains its characteristic dry-mouth side effect.

The FDA has approved Myobloc for two indications in adults. Cervical dystonia (spasmodic torticollis) was its original indication, and chronic sialorrhea, or excessive drooling, followed in 2019. For most payers, these two diagnoses make the strongest medical necessity case without extra step-therapy documentation.

• Cervical dystonia (spasmodic torticollis): Painful involuntary contractions of the neck muscles that cause abnormal head position. Myobloc is indicated in adults to reduce the severity of abnormal head position and neck pain.
• Chronic sialorrhea: Excessive salivary secretion causing drooling in adults. The FDA approved this indication in 2019.
• Off-label uses: Hyperhidrosis, spasticity and other dystonic conditions are sometimes treated with rimabotulinumtoxinB. Billing J0587 for these off-label indications draws payer scrutiny and a high denial risk.

FDA-approved indications and ICD-10 diagnosis codes

The surest route to a J0587 denial is a diagnosis code that doesn’t match an FDA-approved indication. A code outside the governing Local Coverage Determination (LCD) fails the same way. The table below maps each approved indication to its main supporting diagnosis codes.

Billing and coding article A52848, “Billing and Coding: Botulinum Toxins,” sits in the CMS Medicare Coverage Database. It lists J0587 alongside the other toxin codes and confirms that J0587 is billed per 100 units. Review the LCD and billing article for your own MAC jurisdiction before billing any botulinum toxin code.

How to bill HCPCS Code J0587: Unit calculation and dose reporting

J0587 is billed per 100 units of rimabotulinumtoxinB administered. To find the units to report, divide the total dose by 100 and round to the nearest whole number (.5 rounds up). The diagram below follows a 2,500-unit cervical dystonia dose from the chart to the claim.

1. Record the total dose administered in the patient’s chart (for example, 2,500 units of Myobloc for cervical dystonia).
2. Divide by 100 to get the billing units: 2,500 ÷ 100 = 25 units of J0587.
3. Report the NDC number on the claim line where the payer requires it. NDC reporting is required by Medicaid and many commercial payers, so check your payer’s rules. When reported, it follows the qualifier-NDC-quantity-unit format on the CMS-1500 or 837P claim.
4. Apply wastage rules if applicable. Payer policies on billing unused drug differ. Medicare allows wastage billing when it is medically necessary to open a new vial for a single patient and the remainder can’t be used. Document the vial size, the dose administered and the reason for the wastage.
5. Submit with the correct place-of-service code. Medicare pays different rates for non-facility (office, POS 11) and facility (hospital outpatient, POS 22) settings.

J0587 covers the drug only. The injection service itself is billed with a separate administration code, typically CPT 64616 for cervical dystonia. An off-label axillary hyperhidrosis session is billed with 64650 instead, because the administration code follows the site treated rather than the toxin used.

Medicare coverage and reimbursement for J0587

Medicare Part B reimburses J0587 at the Average Sales Price (ASP) plus 6% in non-facility (office) settings. In facility settings, payment falls under the Outpatient Prospective Payment System (OPPS), which typically produces a lower combined rate.

CMS updates ASP-based rates every quarter, so any dollar figure in a static reference may be out of date. Before quoting a rate to a patient or payer, pull it from the CMS Physician Fee Schedule lookup tool or the ASP Drug Pricing File.

• Non-facility (office, POS 11): ASP + 6%, the standard buy-and-bill rate for physician-administered drugs in the office.
• Facility (hospital outpatient, POS 22): The OPPS payment rate, generally lower than the non-facility rate and subject to different cost-sharing rules.
• MAC jurisdiction variation: Medicare Administrative Contractors (MACs) such as Novitas Solutions (JL/JH) and Noridian Healthcare Solutions (JE/JF) may apply different LCD criteria. The ASP-based payment method is the same in every jurisdiction.
• Commercial payers: Reimbursement structures vary. Some payers use AWP-minus contracts and others use their own fee schedules, so verify the contracted J0587 rate with each payer.

Prior authorization and medical necessity requirements

Medicare does not universally require prior authorization (PA) for J0587 under the standard buy-and-bill pathway, but many commercial payers and Medicare Advantage plans do. Check each plan’s PA rules before every course of treatment. Some payers require re-authorization for each treatment cycle, not only the first injection.

Where a payer requires PA, the supporting documentation typically includes:

• A confirmed diagnosis of cervical dystonia or chronic sialorrhea.
• Evidence of prior therapy attempts, since step-therapy rules vary by payer.
• The planned dose and injection sites.
• The treating physician’s attestation of medical necessity.

Matching this documentation to the language of the applicable LCD, rather than sending generic office notes, improves PA approval rates.

• Step therapy: Some payers require documented trial and failure of physical therapy or oral muscle relaxants before approving Myobloc for cervical dystonia.
• Frequency limits: LCDs and payer policies typically allow treatment no more than once every 12 weeks. Billing more often than the governing policy allows triggers an automatic denial. Cite the LCD number and effective date when documenting frequency compliance.
• Re-authorization intervals: Commercial plans often require re-authorization every 6 to 12 months. Track expiration dates in your practice management system so no claim goes out after an authorization lapses.

Documentation requirements for J0587 claims

A J0587 claim that survives a RAC or MAC audit needs more in the medical record than a standard office visit note. A claim that pays without this documentation in place still carries retrospective repayment risk.

Keeping medical billing compliance documentation consistent across every Myobloc encounter protects the practice during post-payment review. The record must support the diagnosis, the dose and the medical necessity decision.

• Physician order: A signed order specifying the drug name (rimabotulinumtoxinB or Myobloc), concentration, dose in units and injection sites.
• Diagnosis documentation: Clinical confirmation of cervical dystonia or chronic sialorrhea, with examination findings or prior diagnostic workup.
• Dose administered: The exact units injected, recorded in the procedure note and not only in the order.
• NDC number and lot number: Record both in the medical record, and report the NDC on the claim where the payer requires it. NDC reporting is required by Medicaid and many commercial payers, so check your payer’s rules. The NDC must match the product administered.
• Purchase invoice: Payers may request proof of acquisition cost during an audit. Retain invoices for all botulinum toxin products.
• Injection site documentation: Record which muscles were injected. For cervical dystonia, this typically means naming the specific neck muscles.

The most defensible approach for botulinum toxin billing is structured superbill documentation. It captures every required field at the time of service, rather than through later addenda.

J0587 vs. other botulinum toxin HCPCS codes

Several HCPCS codes cover botulinum toxin products. The four most often compared are shown below, and their billing unit sizes differ. Billing J0587 at the same unit ratio as J0585, for example, produces systematic over- or under-billing.

In practice, a 500-unit dose of Myobloc is billed as 5 units of J0587. The same 500-unit dose of Botox would be billed as 500 units of J0585. Applying J0585’s per-unit logic to a J0587 claim reports 100 times too many billing units, which payer claim-editing systems flag immediately.

Common claim denial reasons for J0587 and how to avoid them

Most J0587 denials fall into one of six categories, and each has a specific root cause and a fixable workflow step. Handling claim denial management at the code level, rather than only at the appeals stage, cuts the administrative cost of each denial.

Submitting a clean claim for J0587 means every element above is correct on the first submission. Myobloc is often given on a fixed 12-week schedule, so an uncorrected workflow error comes back with every treatment cycle.

When to use J3490 or J3590 instead of J0587

J3490 (unclassified drug) and J3590 (unclassified biologic) are catch-all codes for drugs or biologics with no specific HCPCS code. They are never correct for Myobloc. J0587 is the assigned code for rimabotulinumtoxinB, and using an unclassified code instead typically leads to denial, delayed payment and audit scrutiny.

J3490 or J3590 might appear in a Myobloc billing context in only three scenarios:

• Payer system lag: Occasionally, a payer’s claims system doesn’t yet recognize a recently activated HCPCS code. Contact the payer’s provider relations team before defaulting to J3490, because many payers can process the correct code with a manual override.
• Off-label compounded formulations: If a pharmacy compounds a rimabotulinumtoxinB preparation outside the approved product, the compounded drug may not map to J0587. Compounded botulinum toxin carries its own regulatory risks and sits outside standard billing practice.
• Investigational use: Clinical trial billing follows different rules entirely. Standard commercial billing codes are generally not used for investigational drug administration.

In routine clinical practice, there is no legitimate reason to bill J3490 or J3590 for Myobloc. A rimabotulinumtoxinB claim prepared without J0587 points to a workflow error that needs correcting before submission. Review the CMS HCPCS Level II code set to confirm J0587 remains the active code for rimabotulinumtoxinB.

How claims management software prevents J0587 billing errors

Most J0587 errors start at the point of care. The dose sits in a procedure note, the NDC on a vial label, and the authorization date in a payer portal. A biller then rebuilds the claim from all three by hand.

Pabau, the practice management platform we build, keeps the treatment note, injection sites and stock records in the same patient record. Its claims management software works from that record. The units, NDC and injection details logged at the point of care carry through to the claim.

Scheduling covers the frequency limit. Booking the next Myobloc appointment at least 12 weeks out, with an automated reminder, keeps re-treatment inside the interval most LCDs allow.

Track Myobloc billing from dose to claim

Pabau’s claims management software captures drug units, NDC numbers and injection details at the point of care. J0587 claims go out clean, and the audit documentation is already complete.

Book a demo

Conclusion

J0587 rewards practices that set up the unit conversion once and stop doing it by hand. Put dose ÷ 100 into the charge capture template and check NDC rules payer by payer. Then pair every claim with a diagnosis from your MAC’s LCD.

The trade-off is narrow coverage. With only two FDA-approved indications, an off-label Myobloc claim needs pre-authorization and a documented medical necessity case before the first injection.

To see how Pabau keeps Myobloc doses, NDC numbers and injection records ready for a clean J0587 claim, book a demo.

Continue your research

Need to understand how denials flow through your billing cycle? Denial management in healthcare covers how to build a systematic appeal and prevention process across all claim types.

Billing other botulinum toxins as well? HCPCS code J0586 explains how Dysport is billed in 5-unit increments.

Decoding a denial on a toxin claim? Denial codes in medical billing lists the CARC and RARC codes payers return and what each one asks you to fix.

Want a reference on how drug billing fits into revenue cycle management? What is revenue cycle management explains the full claim lifecycle from encounter to payment posting.

Looking for the broader billing framework? What is medical billing covers the structure that governs how J-codes and other HCPCS drug codes are reimbursed.

Frequently asked questions